Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, a pioneering biopharmaceutical company headquartered in the United States, is at the forefront of RNA interference (RNAi) therapeutics. Founded in 2002, Alnylam has made significant strides in the development of innovative treatments for rare genetic diseases, positioning itself as a leader in the industry. With a strong operational presence in key regions, including Europe and Asia, Alnylam focuses on delivering transformative medicines that target the underlying causes of diseases. Its core products, such as ONPATTRO and GIVLAARI, are distinguished by their unique mechanism of action, offering patients new hope where traditional therapies have fallen short. Recognised for its commitment to scientific excellence, Alnylam has achieved numerous milestones, including the first-ever approval of an RNAi therapeutic, solidifying its market position as a trailblazer in the biopharmaceutical landscape.
DitchCarbon Score
How does Alnylam Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alnylam Pharmaceuticals's score of 60 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alnylam Pharmaceuticals's reported carbon emissions
In 2023, Alnylam Pharmaceuticals reported total carbon emissions of approximately 35,290,000 kg CO2e from Scope 1, 9,933,000 kg CO2e from Scope 2 (market-based), and 3,270,000 kg CO2e from business travel, 2,560,000 kg CO2e from employee commute, and 1,107,000 kg CO2e from waste generated in operations under Scope 3. This data reflects a commitment to transparency in their carbon footprint, with emissions disclosed across all three scopes. Comparatively, in 2022, the company recorded Scope 1 emissions of about 4,095,000 kg CO2e, Scope 2 emissions of 10,116,000 kg CO2e (market-based), and Scope 3 emissions of 2,920,000 kg CO2e from business travel, 2,419,000 kg CO2e from employee commute, and 860,000 kg CO2e from waste. This indicates a reduction in Scope 1 emissions by approximately 805,000 kg CO2e and a slight decrease in Scope 2 emissions. Alnylam Pharmaceuticals has set ambitious reduction targets, aiming to decrease Scope 1 and Scope 2 emissions by 30% from 2020 levels by the year 2030. This commitment underscores their proactive approach to climate action and aligns with industry standards for sustainability. The company’s emissions data is not cascaded from any parent organization, ensuring that their reported figures are solely reflective of their own operations. Alnylam Pharmaceuticals continues to prioritise environmental responsibility as part of its corporate ethos.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 3,054,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 8,518,000 | 0,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 3,064,000 | 0,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alnylam Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
